AI-generated analysis. Always verify with the original filing.
Viemed Healthcare, Inc. announced record Q4 and full year 2025 financial results with net revenues of $76.2 million and $270.3 million, net income of $5.6 million ($0.14 per diluted share) and $14.9 million ($0.37 per diluted share), and authorized a share repurchase program for up to 1,930,131 common shares through March 2027. The company issued 2026 guidance for net revenue of $310-$320 million and Adjusted EBITDA of $65-$69 million.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition On March 4, 2026 , Viemed Healthcare, Inc. (the "Company") issued a press release announcing its financial resul
. Regulation FD Disclosure On March 4, 2026 , the Company also issued a press release announcing that its Board of Directors has approved a share repurchase pro
. Other Events On March 4, 2026 , the Company's Board of Directors authorized and approved a share repurchase program on Nasdaq. Under the terms of the program,
. Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 4 , 202 6 . 99. 2 Financial Supplement dated March 4,
| Metric | Value | Basis |
|---|---|---|
| Revenue | $76.2K | |
| Net Income attributable to Viemed | $5.6K | GAAP |
| Diluted EPS | $0.14 | GAAP |
| Revenue | $270.3K | |
| Net Income attributable to Viemed | $14.9K | GAAP |
| Diluted EPS | $0.37 | GAAP |
Buyback Auth.
1,930,131 common shares through March 2027